Y. Akatsu

Fibroblast growth factor signals regulate transforming growth factor‐β‐induced endothelial‐to‐myofibroblast transition of tumor endothelial cells via Elk1

Hiroshi I. Suzuki, J. Inazawa, K. Miyazono, 2019, Molecular oncology.

Dual targeting of vascular endothelial growth factor and bone morphogenetic protein‐9/10 impairs tumor growth through inhibition of angiogenesis

K. Miyazono, T. Watabe, A. Katsura, 2017, Cancer science.

Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis

K. Miyazono, M. Fukayama, T. Watabe, 2014, Cancer science.

ANovel Compound , NK 150460 , Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor

K. Nishikawa, S. Horie, Y. Satoh, 2015 .

A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor

K. Nishikawa, S. Horie, Y. Satoh, 2014, Molecular Cancer Therapeutics.

Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression

Hiroshi I. Suzuki, T. Zimmers, K. Maruyama, 2013, Proceedings of the National Academy of Sciences.

TGF-β-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A.

Hiroshi I. Suzuki, K. Miyazono, T. Watabe, 2012, Journal of biochemistry.

Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer

K. Miyazono, M. Shirouzu, Hitomi Takahashi, 2020, The Journal of Biological Chemistry.